Semaglutide: weight-loss evidence alongside trial conditions

Evidence discussed: Randomized phase 3 human trial.

What the researchers studied

STEP 3 enrolled 611 adults with overweight or obesity without diabetes. Semaglutide or placebo was combined with an initial low-calorie diet and intensive behavioral support. Average weight reduction at 68 weeks was greater with semaglutide. [1]

How to interpret the result

Gastrointestinal adverse events were more frequent, and some participants stopped treatment because of them. Results describe a clinical formulation within a structured program; they cannot establish equivalence to a research vial.

What readers can take from it

This is stronger clinical evidence than an animal experiment, but the setting remains important. Group averages from selected participants are not individual guarantees or validation of every product carrying the molecule name.

This original editorial summary provides no diagnosis, dosing or treatment advice. The study did not test or certify a PeptiKing product.

Source

[1] Wadden et al., STEP 3 semaglutide trial (2021). PMID: 33625476. Based on the PubMed-indexed abstract and record; full-text methods were not independently reviewed.